GC/MS-based metabolomic analysis of cerebrospinal fluid (CSF) from glioma patients

Journal of Neuro-Oncology

Volumn 113, Issue 1, 2013, Pages 65-74

  Nakamizo, Satoshi ^a   Sasayama, Takashi ^a   Shinohara, Masakazu ^a   Irino, Yasuhiro ^a   Nishiumi, Shin ^a   Nishihara, Masamitsu ^b   Tanaka, Hirotomo ^a   Tanaka, Kazuhiro ^a   Mizukawa, Katsu ^a   Itoh, Tomoo ^a   Taniguchi, Masaaki ^a   Hosoda, Kohkichi ^a   Yoshida, Masaru ^a   Kohmura, Eiji ^a  

^a KOBE UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b NISHI KOBE MEDICAL CENTER   (Japan)

Author keywords

Cerebrospinal fluid; Citric acid; Glioma; Isocitrate dehydrogenase; Lactic acid; Metabolome

Indexed keywords

CITRIC ACID; DIAMINOPIMELIC ACID; GADOLINIUM; ISOCITRATE DEHYDROGENASE; ISOCITRIC ACID; LACTIC ACID;

ADULT; AGED; ARTICLE; CANCER GRADING; CANCER PROGNOSIS; CEREBROSPINAL FLUID; CLINICAL ARTICLE; CONTRAST ENHANCEMENT; CONTROLLED STUDY; FEMALE; GAS CHROMATOGRAPHY; GLIOBLASTOMA; GLIOMA; HISTOPATHOLOGY; HUMAN; MALE; MASS SPECTROMETRY; NUCLEAR MAGNETIC RESONANCE IMAGING; PREOPERATIVE EVALUATION; QUANTITATIVE ANALYSIS; TUMOR LOCALIZATION; WILD TYPE; WORLD HEALTH ORGANIZATION;

ADOLESCENT; ADULT; AGED; BRAIN NEOPLASMS; FEMALE; GAS CHROMATOGRAPHY-MASS SPECTROMETRY; GLIOMA; HUMANS; MALE; METABOLOMICS; MIDDLE AGED; NEOPLASM GRADING; TUMOR MARKERS, BIOLOGICAL; YOUNG ADULT;

EID: 84876926672     PISSN: 0167594X     EISSN: 15737373     Source Type: Journal    
DOI: 10.1007/s11060-013-1090-x     Document Type: Article

References (50)

1. Frankfort SV, Tulner LR, van Campen JP et al (2008) Amyloid beta protein and tau in cerebrospinal fluid and plasma as biomarkers for dementia: a review of recent literature. Curr Clin Pharmacol 3:123-131
2. Helbok R, Broessner G, Pfausler B, Schmutzhard E (2009) Chronic meningitis. J Neurol 256:168-175
3. Lewczuk P, Hornegger J, Zimmermann R et al (2008) Neurochemical dementia diagnostics: assays in CSF and blood. Eur Arch Psychiatry Clin Neurosci 258(Suppl.):44-49
4. Romeo MJ, Espina V, Lowenthal M et al (2005) CSF proteome: a protein repository for potential biomarker identification. Expert Rev Proteomics 2:57-70
5. Diez B, Balmaceda C, Matsutani M, Weiner HL (1999) Germ cell tumors of the CNS in children: recent advances in therapy. Childs Nerv Syst 15:578-585
6. Sasayama T, Nakamizo S, Nishihara M et al (2012) Cerebrospinal fluid interleukin-10 is a potentially useful biomarker in immunocompetent primary central nervous system lymphoma (PCNSL). Neurooncology 14:368-380
7. Louis DN, Ohgaki H, Wiestler OD, Cavenee WK (2007) WHO classification of tumours of the central nervous system, 4th edn. IARC Press, Lyon
8. Burger PC, Scheithauer BW, Paulus W et al (2000) Pilocytic astrocytoma. In: Kleihues P, Cavenee WK (eds) Pathology and genetics of tumours of the nervous system. IARC Press, Lyon, pp 45-51
9. Stupp R, Mason WP, van den Bent MJ et al (2005) Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 352:987-996
10. Wen PY, Kesari S (2008) Malignant gliomas in adults. N Engl J Med 359:492-507
11. Warburg O (1956) On the origin of cancer cells. Science 123:309-314
12. Yamasaki F, Kurisu K, Kajiwara Y et al (2011) Magnetic resonance spectroscopic detection of lactate is predictive of a poor prognosis in patients with diffuse intrinsic pontine glioma. Neurooncology 13:791-801
13. Parsons DW, Jones S, Zhang X et al (2008) An integrated genomic analysis of human glioblastoma multiforme. Science 321:1807-1812
14. Yan H, Parsons DW, Jin G et al (2009) IDH1 and IDH2 mutations in gliomas. N Engl J Med 360:765-773
15. Balss J, Meyer J, Mueller W et al (2008) Analysis of the IDH1 codon 132 mutation in brain tumors. Acta Neuropathol 116:597-602
16. Hartmann C, Meyer J, Balss J et al (2009) Type and frequency of IDH1 and IDH2 mutations are related to astrocytic and oligodendroglial differentiation and age: a study of 1,010 diffuse gliomas. Acta Neuropathol 118:469-474
17. Ichimura K, Pearson DM, Kocialkowski S et al (2009) IDH1 mutations are present in the majority of common adult gliomas but rare in primary glioblastomas. Neurooncology 11:341-347
18. Gupta R, Webb-Myers R, Flanagan S, Buckland ME (2011) Isocitrate dehydrogenase mutations in diffuse gliomas: clinical and aetiological implications. J Clin Pathol 64:835-844
19. Yoshida M, Hatano N, Nishiumi S et al (2012) Diagnosis of gastroenterological diseases by metabolome analysis using gas chromatography-mass spectrometry. J Gastroenterol 47:9-20
20. Hirayama A, Kami K, Sugimoto M et al (2009) Quantitative metabolome profiling of colon and stomach cancer microenvironment by capillary electrophoresis time-of-flight mass spectrometry. Cancer Res 69:4918-4925
21. Lindon JC, Nicholson JK, Everett JR (1999) NMR spectroscopy of biofluids. In: Webb GA (ed) Annual reports on NMR spectroscopy. Academic Press, London, pp 1-88
22. Lutz NW, Viola A, Malikova I et al (2007) Inflammatory multiple-sclerosis plaques generate characteristic metabolic profiles in cerebrospinal fluid. PLoS One 2:e595
23. Kawashima H, Oguchi M, Ioi H et al (2006) Primary biomarkers in cerebral spinal fluid obtained from patients with influenza-associated encephalopathy analyzed by metabolomics. Int J Neurosci 116:927-936
24. Myint KT, Aoshima K, Tanaka S, Nakamura T, Oda Y (2009) Quantitative profiling of polar cationic metabolites in human cerebrospinal fluid by reversed-phase nanoliquid chromatography/mass spectrometry. Anal Chem 81:1121-1129
25. Wuolikainen A, Moritz T, Marklund SL, Antti H, Andersen PM (2011) Disease-related changes in the cerebrospinal fluid metabolome in amyotrophic lateral sclerosis detected by GC/TOFMS. PLoS One 6:e17947
26. Blanchet L, Smolinska A, Attali A et al (2011) Fusion of metabolomics and proteomics data for biomarkers discovery: case study on the experimental autoimmune encephalomyelitis. BMC Bioinformatics 12:254
27. Nishiumi S, Shinohara M, Ikeda A et al (2010) Serum metabolomics as a novel diagnostic approach for pancreatic cancer. Metabolomics 6:518-528
28. Ooi M, Nishiumi S, Yoshie T et al (2011) GC/MS-based profiling of amino acids and TCA cycle-related molecules in ulcerative colitis. Inflamm Res 60:831-840
29. Tsugawa H, Bamba T, Shinohara M et al (2011) Practical non-targeted gas chromatography/mass spectrometry-based metabolomics platform for metabolic phenotype analysis. J Biosci Bioeng 112:292-298
30. Storey JD, Tibshirani R (2003) Statistical significance for genomewide studies. Proc Natl Acad Sci USA 100:9440-9445
31. Vander Heiden MG, Cantley LC, Thompson CB (2009) Understanding the Warburg effect: the metabolic requirements of cell proliferation. Science 324:1029-1033
32. DeBerardinis RJ, Mancuso A, Daikhin E et al (2007) Myc regulates a transcriptional program that stimulates mitochondrial glutaminolysis and leads to glutamine addiction. Proc Natl Acad Sci USA 104:19345-19350
33. Chang SM, Nelson S, Vandenberg S et al (2009) Integration of preoperative anatomic and metabolic physiologic imaging of newly diagnosed glioma. J Neurooncol 92:401-415
34. Colavolpe C, Metellus P, Mancini J et al (2012) Independent prognostic value of pre-treatment 18-FDG-PET in high-grade gliomas. J Neurooncol 107:527-535
35. Wishart DS, Lewis MJ, Morrissey JA et al (2008) The human cerebrospinal fluid metabolome. J Chromatogr 871:164-173
36. Stoop MP, Coulier L, Rosenling T et al (2010) Proteomics and metabolomics analysis of normal human CSF. Mol Cell Proteomics 9:2063-2075
37. Rosenling T, Stoop MP, Smolinska A et al (2011) The impact of delayed storage on the measured proteome and metabolome of human cerebrospinal fluid. Clin Chem 57:1703-1711
38. Hollingworth W, Medina LS, Lenkinski RE et al (2006) A systematic literature review of magnetic resonance spectroscopy for the characterization of brain tumors. AJNR 7:1404-1411
39. Argiles JM, Azcon-Bieto J (1988) The metabolic environment of cancer. Mol Cell Biochem 81:3-17
40. Busch H, Davis JR, Olle EW (1957) Citrate accumulation in slices of transplantable tumors of the rat. Cancer Res 17:711-716
41. Hatzivassiliou G, Zhao F, Bauer DE et al (2005) ATP citrate lyase inhibition can suppress tumor cell growth. Cancer Cell 8:311-321
42. Seymour ZA, Panigrahy A, Finlay JL, Nelson MD Jr, Blüml S (2008) Citrate in pediatric CNS tumors? AJNR Am J Neuroradiol 29:1006-1011
43. Blüml S, Panigrahy A, Laskov M et al (2011) Elevated citrate in pediatric astrocytomas with malignant progression. Neurooncology 13:1107-1117
44. Reitman ZJ, Jin G, Karoly ED, Spasojevic I et al (2011) Profiling the effects of isocitrate dehydrogenase 1 and 2 mutations on the cellular metabolome. Proc Natl Acad Sci USA 108:3270-3275
45. Lazovic J, Soto H, Piccioni D, Lo Ru JR et al (2012) Detection of 2-hydroxyglutaric acid in vivo by proton magnetic resonance spectroscopy in U87 glioma cells overexpressing isocitrate dehydrogenase-1 mutation. Neuro Oncol 14(12):1465-1472
46. Seltzer MJ, Bennett BD, Joshi AD et al (2010) Inhibition of glutaminase preferentially slows growth of glioma cells with mutant IDH1. Cancer Res 70:8981-8987
47. Pope WB, Prins RM, Albert Thomas M, Nagarajan R et al (2012) Non-invasive detection of 2-hydroxyglutarate and other metabolites in IDH1 mutant glioma patients using magnetic resonance spectroscopy. J Neurooncology 107:197-205
48. Dang L, White DW, Gross S et al (2009) Cancer-associated IDH1 mutations produce 2-hydroxyglutarate. Nature 462:739-744
49. Sahm F, Capper D, Pusch S et al (2012) Detection of 2-hydroxyglutarate in formalin-fixed paraffin-embedded glioma specimens by gas chromatography/mass spectrometry. Brain Pathol 22:26-31
50. Locasale JW, Melman T, Song S et al (2012) Metabolomics of human cerebrospinal fluid identifies signatures of malignant glioma. Mol Cell Proteomics 11:M111